{
    "clinical_study": {
        "@rank": "105964", 
        "arm_group": [
            {
                "arm_group_label": "RFA+BT injection", 
                "arm_group_type": "Active Comparator", 
                "description": "Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
            }, 
            {
                "arm_group_label": "RFA", 
                "arm_group_type": "Active Comparator", 
                "description": "Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a \ufb02ow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster)."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this randomized study was to assess the effectiveness of endomyocardial botulinum\n      toxin injection for preventing post-procedural atrial fibrillation in patients undergoing\n      the radiofrequency ablation of atrial flutter."
        }, 
        "brief_title": "Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Flutter", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Atrial Flutter"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years\n\n          -  ECG documented paroxysmal or persistent AFL\n\n          -  No prior documented history of AF\n\n          -  Patient undergoing RFA of AFL.\n\n          -  No indication (other than AFL) for continued anticoagulation with warfarin.\n\n          -  No existing implantable cardiac device (pacemaker, defibrillator, cardiac\n             resynchronization therapy device)\n\n        Exclusion Criteria:\n\n          -  A history of atrial fibrillation\n\n          -  Previous AF ablation procedure\n\n          -  Congestive heart failure\n\n          -  Left Ventricle ejection fraction less than 35%\n\n          -  Unwillingness to participate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02002962", 
            "org_study_id": "BT_AFL"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "RFA+BT injection", 
                    "RFA"
                ], 
                "intervention_name": "radiofrequency ablation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "RFA+BT injection", 
                "intervention_name": "Botulinum Toxin Type A injection", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 2, 2013", 
        "link": {
            "description": "State Research Institute of Circulation Pathology Official Site", 
            "url": "http://meshalkin.ru"
        }, 
        "location": {
            "contact": {
                "email": "E.Pokushalov@gmail.com", 
                "last_name": "Evgeny Pokushalov, MD, PhD", 
                "phone": "+79139254858"
            }, 
            "facility": {
                "address": {
                    "city": "Novosibirsk", 
                    "country": "Russian Federation", 
                    "zip": "630055"
                }, 
                "name": "State Research Institute of Circulation Pathology"
            }, 
            "investigator": {
                "last_name": "Evgeny Pokushalov, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter to Prevent Post-procedural Atrial Fibrillation", 
        "overall_contact": {
            "email": "e.pokushalov@gmail.com", 
            "last_name": "Evgeny Pokushalov, MD, PhD", 
            "phone": "+79139254858"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "number of paroxysms of atrial fibrillation", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02002962"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AF burden", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Meshalkin Research Institute of Pathology of Circulation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Meshalkin Research Institute of Pathology of Circulation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}